Molecular profiles of screen detected vs. symptomatic breast cancer and their impact on survival: results from a clinical series

Table 4 Tumor characteristics by molecular subtypes

	Luminal A			Luminal B			Non-Luminal HER2+			Triple Negative
	N = 267			N = 77			N = 52			N = 36*
	Symptomatic	Screen Detected‡	p-value	Symptomatic	Screen Detected	p-value	Symptomatic	Screen Detected	p-value	Symptomatic	Screen Detected	p-value
	(N, % )	(N, % )		(N, % )	(N, % )		(N, % )	(N, %)		(N, % )	(N, % )
Age			*.001*						*.34*			*.31*
<40 years	24 (12.4)	2 (2.7)		9 (15.3)	0		6 (15.8)	1 (7.1)		4 (11.8)	0
40–49	39 (20.2)	17 823)		16 (27.1)	2 (11.1)		9 (23.7)	6 (42.9)		11 (32.4)	0
50–69	93 (48.2)	51 (68.9)		25 (42.4)	14 (77.8)		18 (47.4)	7 (50)		12 (35.3)	2
≥70	37 (19.2)	4 (5.4)		9 (15.3)	2 (11.1)		5 (13.2)	0		7 (20.6)	0
Tumor size			*<.0001*			*.53*			*.11*			*.14*
T1	103 (55.4)	60 (87)		32 (55.2)	11 (64.7)		16 (44.4)	9 (75)		10 (30.3)	2 (100)
T2	60 (32.3)	9 (13)		22 (37.9)	6 (35.3)		17 (47.2)	2 (16.7)		22 (66.7)	0
T3–T4	23 (12.4)	0		4 (6.9)	0		3 (8.3)	1 (8.3)		1 (3.0)	0
Lymph nodes			*.21*			*.22*			*0.06*			*.31*
None	101 (54.3)	45 (66.2)		27 (47.4)	12 (66.7)		14 (38.9)	11 (91.7)		22 (64.7)	1 (50)
1–3	41 (22)	13 (19.1)		19 (33.3)	5 (27.8)		14 (38.9)	1 (8.3)		4 (11.8)	1 (50)
≥4	44 (23.7)	10 (14.7)		11 (19.3)	1 (5.6)		8 (22.2)	0		8 (23.5)	0
Histological grade			*.006*			*.002*			*.81*			*.81*
1	21 (11.5)	20 (27.8)					1 (2.7)	0
2	88 (48.1)	29 (40.3)		21 (35.6)	14 (77.8)		8 (21.6)	3 (23.1)		1 (3)	0
3	74 (40.4)	23 (31.9)		38 (64.4)	4 (22.2)		28 (75.7)	10 (76.9)		32 (97)	2 (100)
Ki-67			*.15*			*.11*			*.23*			*.72*
≤20%	102 (54.8)	46 (64.8)		22 (37.3)	10 (55.6)		12 (33.3)	2 (16.7)		2 (6.1)	0
>20%	84 (45.2)	25 (35.2)		37 (62.7)	8 (44.4)		24 (66.7)	10 (83.3)		31 (93.9)	2 (100)

ISSN: 1471-2407